Navigation Links
Delcath Highlights First Quarter 2012 And Recent Accomplishments
Date:5/8/2012

NEW YORK, May 8, 2012 /PRNewswire/ -- Delcath Systems (NASDAQ: DCTH) today announced financial results and highlights for its first quarter 2012 ended March 31, 2012 and recent weeks. 

Highlights for the first quarter 2012 and recent weeks include:

  • Receipt of CE Mark approval for the second generation hemofiltration cartridge ("Generation 2") for Hepatic CHEMOSAT® delivery system
  • Treatment of the first patient with Generation 2
  • Additional patients treated with liver dominant metastases from multiple tumor types
  • Presentation of the first evidence of the dramatically improved side-effect profile for chemosaturation therapy with Generation 2
  • Addition of eight EU cancer centers to the CHEMOSAT initial launch and training program; the Company now has a presence in five of its seven target markets
  • Receipt of the first commercial orders for CHEMOSAT
  • Final preparations for filing the new drug application (NDA) for CHEMOSAT with the FDA
  • Regulatory approval in Australia for CHEMOSAT
  • Secure a $20 million working capital credit facility with Silicon Valley Bank
  • Addition of pharmaceutical industry veterans Chris Houchins and Jennifer Simpson, Ph.D. to the management team
  • "During the first quarter, we delivered several significant accomplishments which build on the solid foundation we established in 2011 to help realize the commercial potential of our chemosaturation system," said Eamonn P. Hobbs, President and CEO of Delcath. "The Generation 2 CHEMOSAT system received CE Marking in early April, and we believe that initial validation of the new system's potential to dramatically improve the side-effect profile for chemosaturation therapy was immediately seen in the first case treated with Generation 2.  Prior treatments in Europe also included patients suff
    '/>"/>

    SOURCE Delcath Systems, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
    2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
    3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
    4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
    5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
    6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
    7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
    8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
    9. Delcath Systems, Inc. Completes Phase III Study Enrollment
    10. Delcath Systems Begins Data Analysis of Phase III Trial
    11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
    (Date:1/23/2015)... available for sale, The Armor1 Ankle Roll Guard is a ... by cushioning the ankle from an inversion or "roll." ... of any shoe type and allows the user to ... against sprains. With customers in physical therapy, podiatry, and ...
    (Date:1/23/2015)... 23, 2015   Leatt Corporation  (OTCQB: LEAT), a global ... all forms of sports, including extreme motor sports, and ... today that the UISP Lega Motociclismo Lombardia, an Italian ... to wear a neck brace during its racing competitions.  ...
    Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
    ... Jan. 11, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: ... trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor ... "PARP inihibtors have been validated to show survival benefits ... repair or in combination with DNA damaging agents, and BMN ...
    ... Wis., Jan. 11, 2011 RF Technologies®, a ... and healthcare security solutions, has announced a distributor ... leading provider of medical equipment management and service ... on November 1, UHS will offer the RF ...
    Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3RF Technologies® Announces Distributor Agreement With Universal Hospital Services 2
    (Date:1/22/2015)... 2015 Woodloch Pines, an all-inclusive family ... by TripAdvisor as the number one best large hotel for ... the world for their annual Travelers’ Choice Awards. , ... The website is home to millions of unbiased and honest ...
    (Date:1/22/2015)... 2015 Padre Murphy's and Owner Tom Boyle ... Pro Player Health Alliance (PPHA). The PPHA's passion for ... everyone, including NFL greats, treated for obstructive sleep apnea (OSA) ... supporting the cause in the valley. The most recent plans ...
    (Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together by ... up to 30lbs in less than 12 weeks without traditional ... prompting an investigative review. , “Our Incredible Bulk review ... that allows the body to pack on a massive amount ...
    (Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
    (Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
    Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
    ... reports from government health officials and the World Health Organization, ... She is the virus’ first human victim, in a year ... Mon Puthy, had been in close proximity with sick and ... 40 miles west of Phnom Penh. According to WHO spokeswoman ...
    ... resonance imaging (MRI) has been found to be insufficient, ... ,MRI has been adopted in England and Wales ... (NICE) as part of the recommended criteria for diagnosing ... evidence has not previously been systematically assessed. ...
    ... Organization (WHO) and UNICEF have announced a new formula ... is designed to minimize the occurrence of acute diarrhoeal ... agencies achieve the target of reducing child mortality by ... cause of child mortality and kills nearly 2 million ...
    ... caused by hereditary predisposition. Atopy is a determining factor ... allergens may help prevent adults from developing asthma.//,Journal of ... atopy and specific IgE to mites and molds important ... conducted by Maritta S. Jaakkola, MD, DSc, of the ...
    ... Minister of Bihar Mr. Nitish Kumar is all for a ... used to cultivate potato, tomato and green vegetables// at their ... resource centre for herbal farming. ,Nitish Kumar comes ... was a leading ayurvedic practitioner in his home district of ...
    ... With the announcement of the Food Standards Agency (FSA), that the ... day, and that the tinned foods// should clearly mention the amount ... issue has now picked up, with groups on either side. ... government of UK, has announced targets for reducing salt in a ...
    Cached Medicine News:Health News:MRI Scan Insufficient For Diagnosing Multiple Sclerosis 2Health News:Salt & Its Intake Causes a Strong debate In UK 2
    ... Endoscopic CycloPhotocoagulation (ECP) is a surgical approach ... and visualized laser application. The ciliary body ... the surgeon, from the anterior or posterior ... The target tissues are easily and accurately ...
    ... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
    ... Centuries of German Craftsmanship have ... in the world. Ocutek® now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
    ... Centuries of German Craftsmanship have ... in the world. Ocutek® now ... Only holders of the coveted ... eight-year apprenticeship, are qualified to ...
    Medicine Products: